MK2206 is an allosteric inhibitor of AKT that has shown preclinical synergy with both ibrutinib and venetoclax, potentially enhancing apoptosis in resistant CLL cells [136]. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.